Analysis Version
v1
History
Back to Study: #247 The effect of pravastatin on insulin resistan...
causal
Analysis v1
Strong Support

Taking pravastatin for 12 weeks didn’t make the body better or worse at using insulin to control blood sugar in people with early-stage kidney disease who don’t have diabetes.

47
Pro
0
Against

Evidence from Studies

Supporting (1)

47

Community contributions welcome

47

#247 The effect of pravastatin on insulin resistance in patients with CKD stage 1-3. A randomized, placebo-controlled cross over trial

Randomized Controlled Trial
Human

This study gave people with early kidney disease pravastatin for 12 weeks and checked if their body’s ability to use insulin changed. It found no meaningful difference compared to when they took a placebo, which means the drug didn’t hurt or help their insulin sensitivity.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

#247 The effect of pravastatin on insulin resistance in patients with CKD stage 1-3. A randomized, placebo-controlled cross over trial

Score: 47
DOI: 10.1093/ndt/gfaf116.1325

Similar Assertions

Taking pravastatin for 12 weeks didn't make the body better or worse at using insulin to control blood sugar in people who had a kidney transplant and don't have diabetes.

47
0
92%

After drinking a sugary solution, people with early kidney disease who took pravastatin had no meaningful difference in their blood sugar two hours later compared to those who took a sugar pill.

47
0
92%

Taking pravastatin for 3 months didn’t raise or lower average blood sugar or long-term blood sugar control in people with early kidney disease who don’t have diabetes.

47
0
91%

After drinking a sugary solution, pravastatin didn't make blood sugar rise more or less than a placebo in kidney transplant patients without diabetes.

47
0
85%

Taking pravastatin for 3 months didn't raise or lower average blood sugar or long-term glucose control in kidney transplant patients without diabetes.

47
0
83%